© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
January 17, 2022
Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
November 20, 2021
Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
November 18, 2021
Experts discussed using CD19-targeted agents in patients with various subtypes of diffuse large B-cell lymphoma.
August 02, 2021
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
September 23, 2020
John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.